The Board of Directors of
The exercise prices in the agreement for Feng is maintained at
All options being exercised into shares during the duration period will be subject to a "lock-in" period of 12 months from the time of exercise, where the shares cannot be sold or transferred without the consent of the Board.
After this,
Notifications of transactions by persons discharging managerial responsibilities are attached hereto.
This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities Trading Act § 5-12.
For more information, please contact:
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.
https://news.cision.com/arctic-bioscience-as/r/arctic-bioscience---extension-of-share-options-to-members-of-management-group,c3946580
https://mb.cision.com/Public/20422/3946580/be242ad807871d26.pdf
(c) 2024 Cision. All rights reserved., source